Skip directly to search Skip directly to A to Z list Skip directly to site content
CDC Home

Volume 15, Number 7—July 2009

Dispatch

Lack of Macrolide Resistance in Chlamydia trachomatis after Mass Azithromycin Distributions for Trachoma

Kevin Cyrus Hong, Julius Schachter, Jeanne Moncada, Zhaoxia Zhou, Jenafir House, and Thomas M. LietmanComments to Author 
Author affiliations: University of California, San Francisco, California, USA

Main Article

Table

Antimicrobial drug susceptibilities of Chlamydia trachomatis, Ethiopia*

Treatment status Serotype Azithromycin†
Doxycycline†
MIC MCC MIC MCC
4 biannual A/Har13 0.5 0.5 0.03 0.03
Ba/Apache-2 0.5 0.5 0.03 0.03
Ba/Apache-2 0.5 0.5 0.03 0.06
Ba/Apache-2 0.25 0.5 0.03 0.06
Ba/Apache-2 0.5 0.5 0.03 0.06

Ba/Apache-2
0.5
0.5

0.03
0.03
None A/Har 13 0.5 0.5 0.03 0.03
A/Har 13 0.5 0.5 0.03 0.03
A/Har 13 0.5 1 0.015 0.06
Ba/Apache-2 0.25 0.25 0.03 0.03

*Samples taken in 2006, 18 months after 4 biannual treatments in 2003–2004. MCC, minimum chlamydicidal concentration.
†MIC and MCC values given in μg/mL.

Main Article

Top of Page

USA.gov: The U.S. Government's Official Web PortalDepartment of Health and Human Services
Centers for Disease Control and Prevention   1600 Clifton Rd. Atlanta, GA 30333, USA
800-CDC-INFO (800-232-4636) TTY: (888) 232-6348 - Contact CDC–INFO